Production (Stage)
Channel Therapeutics Corporation
CHRO
$1.22
-$0.0065-0.53%
AMEX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 121.73% | -315.68% | |||
| Gross Profit | -121.73% | 315.68% | |||
| SG&A Expenses | 6.49% | -5.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.49% | -10.90% | |||
| Operating Income | -0.49% | 10.90% | |||
| Income Before Tax | -2.12% | -13.69% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2.12% | -13.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.12% | -13.69% | |||
| EBIT | -0.49% | 10.90% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -0.60% | -9.09% | |||
| Normalized Basic EPS | -0.60% | 10.14% | |||
| EPS Diluted | -0.60% | -9.09% | |||
| Normalized Diluted EPS | -0.60% | 10.14% | |||
| Average Basic Shares Outstanding | 1.51% | 4.22% | |||
| Average Diluted Shares Outstanding | 1.51% | 4.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||